These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27492900)

  • 1. Platelet-vessel wall interactions and drug effects.
    Twarock S; Bagheri S; Bagheri S; Hohlfeld T
    Pharmacol Ther; 2016 Nov; 167():74-84. PubMed ID: 27492900
    [No Abstract]   [Full Text] [Related]  

  • 2. The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy.
    Warner TD; Armstrong PC; Chan MV; Knowles RB
    Expert Rev Hematol; 2016 Mar; 9(3):223-5. PubMed ID: 26822235
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the effect of acetylsalicylic acid at ultra low dose on the interaction platelets/vessel wall?
    Lalanne MC; Doutremepuich C; de Sèze O; Belon P
    Thromb Res; 1990 Nov; 60(3):231-6. PubMed ID: 2084952
    [No Abstract]   [Full Text] [Related]  

  • 5. Shear stress modulates the interaction of platelet-secreted matrix proteins with tumor cells through the integrin alphavbeta3.
    Lawler K; Meade G; O'Sullivan G; Kenny D
    Am J Physiol Cell Physiol; 2004 Nov; 287(5):C1320-7. PubMed ID: 15240342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent therapeutic approaches to platelet activation in coronary artery disease.
    Tousoulis D; Paroutoglou IP; Papageorgiou N; Charakida M; Stefanadis C
    Pharmacol Ther; 2010 Aug; 127(2):108-20. PubMed ID: 20546778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
    Christensen KH; Grove EL; Würtz M; Kristensen SD; Hvas AM
    Platelets; 2015; 26(3):230-5. PubMed ID: 24750015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet interactions as therapeutic targets for prevention of atherothrombosis.
    Smid J; Braun-Dullaeus R; Gawaz M; Langer HF
    Future Cardiol; 2009 May; 5(3):285-96. PubMed ID: 19450054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet receptor desensitization induced by elevated prostacyclin levels causes platelet-endothelial cell adhesion.
    Darius H; Binz C; Veit K; Fisch A; Meyer J
    J Am Coll Cardiol; 1995 Sep; 26(3):800-6. PubMed ID: 7543911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K; Halushka PV; Yan YT; Wong PY
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
    Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The membrane expression of P-selectin, but not monocyte-platelet aggregates, is influenced by variability in response to aspirin in patients with coronary artery disease.
    Kuzniatsova N; Shantsila E; Lip GY; Blann AD
    Platelets; 2014; 25(2):142-3. PubMed ID: 23216649
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
    Heitzer T; Ollmann I; Köke K; Meinertz T; Munzel T
    Circulation; 2003 Aug; 108(5):536-41. PubMed ID: 12874186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thrombocyte inhibitors in cardiovascular therapy].
    Lüscher TF; Pfisterer M
    Schweiz Rundsch Med Prax; 1990 Sep; 79(39):1132-41. PubMed ID: 2218249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A brief review on high on-aspirin residual platelet reactivity.
    Pettersen AA; Arnesen H; Seljeflot I
    Vascul Pharmacol; 2015; 67-69():6-9. PubMed ID: 25869498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet adhesion on endothelium early after vein grafting mediates leukocyte recruitment and intimal hyperplasia in a murine model.
    Tseng CN; Chang YT; Lengquist M; Kronqvist M; Hedin U; Eriksson EE
    Thromb Haemost; 2015 Apr; 113(4):813-25. PubMed ID: 25518998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD.
    Müller KA; Chatterjee M; Rath D; Geisler T
    Thromb Haemost; 2015 Aug; 114(3):498-518. PubMed ID: 26224127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.
    Larsen SB; Grove EL; Kristensen SD; Hvas AM
    Thromb Haemost; 2013 May; 109(5):920-9. PubMed ID: 23407706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelets, inflammation and anti-inflammatory drugs in ACS and CAD.
    Schrör K; Huber K
    Thromb Haemost; 2015 Aug; 114(3):446-8. PubMed ID: 26288949
    [No Abstract]   [Full Text] [Related]  

  • 20. Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction.
    Polzin A; Rassaf T; Böhm A; Lüth A; Kleuser B; Zeus T; Kelm M; Kroemer HK; Schrör K; Rauch BH
    Int J Cardiol; 2013 Dec; 170(2):e23-4. PubMed ID: 24169533
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.